{"id":"NCT00265343","sponsor":"Organon and Co","briefTitle":"6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)","officialTitle":"A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine With Olanzapine in Subjects Who Completed the Protocol 25543 (NCT 00212836; P05817)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2007-12","completion":"2008-01","firstPosted":"2005-12-14","resultsPosted":"2010-02-23","lastUpdate":"2022-02-09"},"enrollment":306,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"asenapine","otherNames":[]},{"type":"DRUG","name":"olanzapine","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"This is an extension study to further test\n\nthe efficacy and safety of asenapine compared with a\n\nmarketed agent (olanzapine) in the treatment of patients with\n\npersistent negative symptoms of schizophrenia.","primaryOutcome":{"measure":"Long-term Change in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale","timeFrame":"Baseline of Protocol 25543 (NCT 00212836) to 365 days (total time for both protocols 25543 & 25544)","effectByArm":[{"arm":"Asenapine","deltaMin":-16.9,"sd":0.98},{"arm":"Olanzapine","deltaMin":-15.4,"sd":0.85}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22198451"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":134},"commonTop":["Headache","Weight increased","Influenza","Schizophrenia"]}}